After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded funds that target the small and mid cap segments.
…
VIEW ARTICLE
If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.